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Introduction
Agreement on the Trans-Pacific Partnership (TTP) in 2015 
sent ripples of concern through the public health community. 
During negotiations stretching over five and a half years, 
public health advocates and researchers mounted a sustained 
campaign to identify potential concerns for health through 
analyses of leaked text and interaction with negotiators. 
Despite this concerted effort, the final text contains various 
provisions with negative implications for public health. 
The paper by Ronald Labonté and colleagues in the July issue 
of the International Journal of Health Policy and Management 
presents a summary analysis of the potential impact on health 
of the world’s largest trade and investment agreement, the 
TTP Agreement.1 A strength of this study is its use of the 
recently published text of the TPP to identify the implications 
of specific provisions for health and health policy-making. 
This analysis identified notable public health ‘wins’ evident 
in the TPP text. However, it also supports the conclusions of 
previous research: international economic policy agreements 
can have a significant negative impact on health.
What We Know About the Problem: Trade-Health Policy 
Incoherence
In the past decade, we have learned much about the 
implications of trade agreements for public health. There is 
potential for trade policy to contribute to equitable economic 
growth, in certain circumstances. In practice, however, trade 
and investment liberalization over the past six decades has 
coincided with ‘highly unequal patterns of income and wealth 
distribution.’2 There has also been increasing recognition 
of incoherence between outcomes of trade and investment 
liberalization, and goals of health policy.3 Policy coherence 
refers to the ‘systematic application of mutually reinforcing 
policies and integration of development concerns across 
government departments to achieve development goals 
along with national policy objectives.’4 The Sustainable 
Development Goals have prioritised policy coherence at the 
national and international level in Goal 17, following on from 
the Addis Ababa Accord.5
Quantitative studies and targeted health impact assessments 
have identified specifically how trade and investment 
agreements can reduce equity in access to health services, 
increase flows of commodities of public health concern 
(such as tobacco and unhealthy foods) and reduce access 
to medicines.1,6-11 Policy analyses of trade and investment 
agreement texts have highlighted the potential for specific 
provisions to limit access to medicines12,13 and constrain policy 
space for health, which refers to the scope that governments 
have to pursue policy priorities.14-16 Economic studies have 
also demonstrated the increased costs associated with 
provisions that expand and prolong monopolies on medicines 
and delay the availability of affordable generics.17,18 Case 
studies have illustrated the threat of investor-state dispute 
settlement (ISDS) mechanisms that enable corporations to 
claim compensation from governments in certain situations 
where their investments have been negatively affected by 
government action.19,20
The recognition that trade agreements need to allow policy 
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In a recent contribution to the ongoing debate about the role of power in global health, Gorik Ooms emphasizes the normative underpinnings of global health politics. 
He identifies three related problems: (1) a lack of agreement 
among global health scholars about their normative premises, 
(2) a lack of agreement between global health scholars and 
policy-makers regarding the normative premises underlying 
policy, and (3) a lack of willingness among scholars to 
clearly state their ormative premises and assumptions. This 
confusio  is for Ooms one of the explanations “why global 
health’s policy-makers are not implementing the knowledge 
generated by global health’s empirical scholars.” He calls 
for greater unity between scholars and between scholars 
and policy-makers, concerning the underlying normative 
premises and greater openness when it comes to advocacy.1
We commend the effort to reinstate power and politics in 
global health and agree that “a purely empirical evidence-based 
approach is a fiction,” and that such a view risks covering up 
“the role of politics and power.” But by contrasting this fiction 
with global health research “driven by crises, hot issues, and 
the concerns of organized interest groups,” as a “path we are 
trying to move away from,” Ooms is submitting to a liberal 
conception of politics he implicitly criticizes the outcomes 
of.1 A liberal view of politics evades the constituting role of 
conflicts and reduces it to either a rationalistic, economic 
calculation, or an individual question of moral norms. This 
is ech ed in Ooms when he states that “it is not possible to 
discuss the politics of global health without discussing the 
normative premises behind the politics.”1 But what if we 
take the political as the primary level and the normative as 
secondary, or derived from the political?
That is what we will try to do here, by introducing an 
alternative conceptualization of the political and hence free 
us from the “false dilemma” Ooms also wants to escape. 
“Although constructivists have emphasized how underlying 
normative structures constitute actors’ identities and 
interests, they have rarely treated these normative structures 
themselves as defined and infused by power, or emphasized 
how constitutive eff c  als  are expressions f power.”2 Thi  
is the starting point for the p litical theorist Chantal Mouffe,
and her resp nse is to develop an ontologi al conception of 
the political, where “the political belongs to ur ontological 
condition.”3 According to Mouffe, society is instituted 
through conflict. “[B]y ‘the political’ I mean the dimension of 
antagonism which I take to be constitutive of human societies, 
while by ‘politics’ I mean the set of practices and institutions 
through which an order is created, organizing human 
coexistence in the context of conflictuality provided by the 
political.”3 An issue or a topic needs to be contested to become 
political, and such a contestation concerns public action and 
creates a ‘we’ and ‘they’ form of collective identification. But 
the fixation of social relations is partial and precarious, since 
antagonism is an ever present possibility. To politicize an issue 
and be abl  to mobilize support, one needs to represent th
world i  a conflictual manner “with oppo ed c mps 
which people c  identify.”3 
Ooms uses the case of “increasing international aid spending 
on AIDS treatment” to illustrate his point.1 He frames the 
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clearly state t eir r ative re ises a  ass ti s. is 
c f si  s f r s e f t e ex la ati s “ y gl al 
ealt ’s licy- akers are t i le e ti g t e k le ge 
ge erate  y gl al ealt ’s e irical sc lars.” e calls 
f r greater ity et ee  sc lars a  et ee  sc lars 
a  licy- akers, c cer i g t e erlyi g r ative 
re ises a  greater e ess e  it c es t  a v cacy.1
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space for governments to achieve other policy objectives, 
including public health, has also proved challenging to 
translate into practice. Most trade agreements incorporate the 
general exception in Article XX of the General Agreement on 
Tariffs and Trade for measures ‘necessary to protect human, 
animal or plant life or health,’21 which is intended to protect 
the right to regulate in the public interest, including for health 
purposes. However, the interpretation of this exception is a 
contested issue and its application is determined by arbitrators 
in the event of a dispute. 
Trade policy-making takes place in an environment where 
industry voices are prominent and where public health 
concerns tend to be marginalised. In many cases, trade policy 
is influenced by industry to achieve objectives related to profit, 
with little consideration of implications for public health.22 
Powerful lobby groups representing the economic interests 
of pharmaceutical, health services, agriculture, food, tobacco, 
and alcohol industries are seeking to strategically influence 
negotiations of trade and investment agreements.23-26 Indeed, 
provisions in recently signed agreements also explicitly 
provide for industry involvement in domestic policy-
making.1,14
Progress Towards Coherence
Despite these ongoing challenges, there has been some 
progress in moving towards policy coherence. One example is 
the exemption or ‘carve-out’ of tobacco control measures from 
ISDS in the TPP Agreement (Article 29.5). This means that 
for countries that elect to employ the exemption, the tobacco 
industry will not be able to use ISDS to seek compensation 
for tobacco control measures, in the manner in which 
tobacco company Phillip Morris has challenged tobacco 
plain packaging in Australia and large health warnings in 
Uruguay.27 However, even this safeguard is limited: it does not 
apply to the whole TPP text but is restricted to ISDS, meaning 
that tobacco companies may still be able to persuade states 
to pursue disputes on their behalf. Of even greater concern is 
that there are no exemptions for policy measures to address 
other public health issues such as the sale, marketing and 
labelling of alcohol and processed foods.27
Another example is the resistance shown by the non-US TPP 
countries to the US agenda to extend and expand monopolies 
on new medicines. Leaks of successive drafts of the TPP 
intellectual property chapter raised alarm amongst health and 
development organisations, resulting in considerable public 
pressure on governments to ensure that medicines remained 
affordable.28 As a result, some of the original US proposals 
were excluded from the TPP, and others were mitigated to 
a significant degree.29,30 However, provisions included in 
the final text of the TPP will still have a significant impact 
on access to medicines in developing countries, which were 
successful in securing only short and inflexible transition 
periods for implementation.1
New Opportunities to Engage With a Changing Trade and 
Investment Agenda
A challenge for public health researchers is the need to engage 
with highly politicized and evolving economic agendas. The 
trade and investment agenda itself is changing. Multilateral 
negotiations at the World Trade Organization (WTO) have 
continued to stall, and there is substantial disagreement 
among major players about whether the WTO’s agenda should 
continue to focus on development, or on ‘new approaches’ 
for ‘meaningful outcomes’ in trade negotiations.31 New 
large-scale regional agreements, such as the TPP and Trans-
Atlantic Trade and Investment Partnership (TTIP), have been 
celebrated as emerging from the multilateral vacuum to drive 
trade and investment liberalization forward.32,33 However, 
both of these agreements appear to have diminishing chances 
of ever entering into force.34
At the same time, the United Nations Conference on Trade and 
Development (UNCTAD) reports increasing dissatisfaction 
with ISDS processes, including a perception of bias towards 
investors among arbitrators of disputes.35 The Government of 
South Africa and Government of India have recently made 
the policy decision to terminate the majority of their bilateral 
investment treaties, in the interests of protecting policy space 
for domestic priorities. A range of model bilateral investment 
treaties at the national and regional level now contain very 
specifically circumscribed definitions of investment and 
the protections that will be offered to foreign investors, in 
an effort to expand domestic policy space.2,35 Countries are 
introducing a range of new approaches to preserve the right 
to regulate and ensure responsible development.35
Overall, these trends speak to a broader dissatisfaction with 
– and perhaps even destabilization of – the neoliberal regime 
that has dominated economic policy discourse, highlighted 
recently by a critique of neoliberalism from within the 
International Monetary Fund.36 With core beliefs of this 
regime being repeatedly challenged in the wake of the global 
financial crisis, some have identified disorganization in the 
global economic policy regime as representing an opportunity 
for new theories and discourses to shape policy directions.37-39
There is an opportunity now for public health researchers and 
practitioners to contribute to this discourse a vision for trade 
and investment policy that protects and supports equitable 
public health outcomes.40 This vision would encompass 
a strategic understanding of opportunities for coherence 
between health and economic policy, and concrete policy 
options to achieve both health and economic policy goals. 
For public health to speak effectively into these changing 
discourses will, however, require new directions in research 
and practice.
What Are the Future Needs for Public Health Research and 
Practice?
Politics and Power
Further nuanced analyses of the consequences of trade and 
investment policy for public health will continue to help in 
identifying specific provisions of concern. However, there is 
also a need to turn public health attention to how solutions 
can be implemented. One aspect of this is to continue to 
provide technical input to trade and investment policy-
makers regarding specific policy options to protect and 
promote public health. 
However, to effect change in the trade and investment agenda 
we must also address politics and power.41,42 One key issue is 
to understand the roles and avenues of influence of different 
stakeholders, including industry actors, and how embedded 
power relationships function to prevent (or support) change 
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for public health (see, for example, Gleeson et al23). This will 
require research that examines how industry exerts power in 
economic policy arenas, and how diverse stakeholder interests 
can be managed. A second but equally important issue is the 
imbalance of economic and political power that often exists 
in trade negotiations between developed and developing 
countries; this requires insights from political science about 
the dynamics of negotiations and how structural power is 
exercised through networks and coalitions, as demonstrated 
in Peter Drahos’ analysis of negotiations over access to 
medicines at the WTO.43
Engaging with questions of power and influence will also be 
vital to identifying opportunities for real progress towards 
policy coherence. This will include research that examines 
economic policy-maker perceptions of the policy space 
available to them, constraints due to global commitments, 
and underlying priorities.44 Understanding these dynamics 
can help identify specific opportunities to change discourse 
and policy-making to advance public health interests. 
Analysing power and political dynamics at multiple levels – 
global, regional, and national – will enhance public health 
understanding of potential points of intervention that could 
bridge silos within policy-making and help to identify 
alternative paradigms, to promote policy coherence between 
economic priorities and health objectives. 
 
Capacity Building
Public health researchers and practitioners can play a valuable 
role in increasing capacity of governments to put public 
health issues on the trade agenda. However, this will require 
training of public health policy-makers and practitioners to 
‘analyse political context and understand complexities, and to 
frame arguments and act effectively in the political arena’ – 
capacities that are often overlooked.45 Policy-oriented capacity 
building would improve the ability of public health policy-
makers and practitioners to engage in two key ways. First, 
being better equipped to speak into trade policy negotiation 
and implementation to ensure that flexibilities, exceptions 
and new processes for dispute settlement are negotiated and 
implemented in ways that support positive public health 
outcomes. This will require not only technical knowledge, but 
also appropriate language and knowledge of avenues through 
which to communicate potential implications for public 
health.46 Second, supporting public health capacity to develop 
strong arguments to counter industry advocacy, that give 
more prominence to health concerns.6,14,26 This necessitates 
engagement with political and economic agendas, and can 
support the development of new discourses around achieving 
policy coherence between trade and health.
Efforts to increase public health capacity also need to address 
national implementation of trade agreements. There is scope 
at the ratification and implementation stage to mitigate 
potential impact on health inequalities.47 Strong regional 
support and capacity building for health can also establish 
norms or policy frameworks to provide a counterbalance to 
regional trade commitments.46,48
Conclusion
The negative impacts of trade and investment agreements 
on public health outcomes and policy-making are becoming 
increasingly clear. Technical support provided by public 
health academics, advocates and practitioners has so far 
proved helpful in preventing and mitigating these effects, but 
alone is insufficient in ensuring protection for public health. 
To effect change, public health must turn attention to political 
and economic agendas that are heavily influenced by industry 
actors. These actors stand to gain a lot from provisions that 
may potentially have negative public health effects. Research 
into politics and power in trade agreements, and investment 
in capacity building should be key pillars of the next phase 
of public health research and practice regarding trade and 
investment policy. 
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